Corgenix Joins Strategic Partners, Presents Science at AACC Meeting and Clinical Lab Expo 2014

July 22, 2014

Corgenix to exhibit AspirinWorksÒ Test, present abstracts, including “best abstract” for Ebola research and first-ever oral presentation.

DENVER — July 22, 2014 — Corgenix Medical Corporation (OTC BB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, will collaborate with strategic partners and also present several scientific abstracts at the American Association for Clinical Chemistry (AACC) Annual Meeting and Clinical Lab Expo 2014 in Chicago.

Corgenix will exhibit its AspirinWorks® (11dhTxB2) Test at AACC July 29 to July 31, 2014, in booth No. 3735. Also featured will be the SkyLAB752™ instrument from strategic partner AXA Diagnostics; SkyLAB752 is the fastest automated ELISA instrument for processing the Corgenix AspirinWorks assay. Corgenix will have an additional presence in strategic partner ELITech Group’s booth No. 741 where several Corgenix products will be on display, including the AspirinWorks/11dhTxB2 and Hyaluronic Acid Test Kits.

Among its five scientific presentations, Corgenix has been awarded Best Annual Meeting Abstract for AACC 2014 in the Critical and Point of Care Testing Division for Infectious Disease poster B-068 titled “Development of a Point-of-Care Diagnostic for Ebola and Sudan Virus Detection.” The company is also presenting an oral abstract of Clinical Studies/Outcomes poster A-143 titled “Suspected Lassa Fever (LF) Case Outcomes: A Comparison to a Non-Febrile Population in Sierra Leone.” The oral abstract will be presented at 11:30 a.m. during the Thursday, July 31, 2014, morning symposia titled “Infected: Innovative Ideas in Laboratory Medicine for Acute and Chronic Infections.”

The three additional Corgenix poster abstracts to be presented during AACC 2014 are 1) Cardiac Markers poster B-356: “An Immunoturbidimetric Assay for the Detection of Thromboxane Metabolites in Urine;” 2) Hematology/Coagulation poster A-296: “A Dual Monoclonal Antibody Chemiluminescent ELISA for the Detection of Hepcidin-25;” and 3) Infectious Disease poster

B-079: “An Immunoturbidimetric Assay for Hyaluronic Acid.”

Corgenix representatives will be available during the conference to answer questions about the AspirinWorks Test and other products, including its diagnostic kits for immunology disorders, vascular diseases, and bone and joint disorders.

AspirinWorks is a simple, non-invasive lab test performed on a urine specimen, which helps doctors accurately determine aspirin effect in apparently healthy individuals by measuring levels of 11-dehydro thromboxane B2 (11dhTxB2). High levels of 11dhTxB2, a metabolite of thromboxane — the target of aspirin therapy — heighten the risk of cardiovascular events, including stroke, myocardial infarction and cardiac death. The goal of aspirin therapy is to reduce levels of thromboxane in the blood, decreasing platelet stickiness and therefore reducing the chance of forming a blood clot.

Unlike other functional platelet tests that require freshly drawn blood that must be evaluated in five hours, the AspirinWorks Test is performed on a random urine sample that can be obtained in any doctor’s office. Physicians and laboratories interested in ordering the test can call 1-800-729-5661 x180, or email More information is also available at

The Hyaluronic Acid Test Kit has not been cleared or approved for diagnostic use in the United States by the U.S. Food and Drug Administration. However, it is CE marked for diagnostic use in the European Union.

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases (including the world’s only non-blood-based test for aspirin effect), bone and joint disorders and a line of unique detection products for viral hemorrhagic disease. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience in product submissions to the FDA and other worldwide regulatory authorities. Additionally, Corgenix contract develops and manufactures products for key medical and life science companies in state-of-the-art facilities in Colorado. The company operates under a Quality Management System that is ISO 13485:2012 certified and compliant with FDA regulations. More information is available at (Corporate website) and (Contract Services website).

Statements in this press release that are not strictly historical facts are “forward-looking” statements (identified by the words “believe”, “estimate”, “project”, “expect” or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company’s products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company’s periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.


Company Contact:

Corgenix Medical Corp.

William Critchfield, Senior VP and CFO

Phone: 303-453-8903



Media Contact:

Armada Medical Marketing

Dan Snyders, Vice President and Public Relations Supervisor
Phone: 303-623-1190 x230